ATE231729T1 - Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff - Google Patents

Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff

Info

Publication number
ATE231729T1
ATE231729T1 AT96927102T AT96927102T ATE231729T1 AT E231729 T1 ATE231729 T1 AT E231729T1 AT 96927102 T AT96927102 T AT 96927102T AT 96927102 T AT96927102 T AT 96927102T AT E231729 T1 ATE231729 T1 AT E231729T1
Authority
AT
Austria
Prior art keywords
japanese encephalitis
pct
virus
vaccine
cells
Prior art date
Application number
AT96927102T
Other languages
English (en)
Inventor
Bernard Fanget
Alain Francon
Pierre Heimendinger
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26232139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE231729(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9509374A external-priority patent/FR2737412B1/fr
Priority claimed from FR9603638A external-priority patent/FR2746411B3/fr
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE231729T1 publication Critical patent/ATE231729T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96927102T 1995-08-01 1996-07-29 Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff ATE231729T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9509374A FR2737412B1 (fr) 1995-08-01 1995-08-01 Procede de production d'un vaccin contre le virus de l'encephalite japonaise et vaccin obtenu par ce procede
FR9603638A FR2746411B3 (fr) 1996-03-22 1996-03-22 Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
PCT/FR1996/001195 WO1997004803A1 (fr) 1995-08-01 1996-07-29 Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu

Publications (1)

Publication Number Publication Date
ATE231729T1 true ATE231729T1 (de) 2003-02-15

Family

ID=26232139

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96927102T ATE231729T1 (de) 1995-08-01 1996-07-29 Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff

Country Status (11)

Country Link
US (1) US6149917A (de)
EP (1) EP0841942B2 (de)
JP (1) JPH11510151A (de)
KR (1) KR19990036028A (de)
CN (1) CN1122531C (de)
AT (1) ATE231729T1 (de)
AU (1) AU709584B2 (de)
CA (1) CA2228128C (de)
DE (1) DE69626022T3 (de)
NZ (1) NZ315357A (de)
WO (1) WO1997004803A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6207439B1 (en) 1997-03-25 2001-03-27 Center For Disease Control Purification of Japanese encephalitis virus
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
KR20010032699A (ko) 1998-10-05 2001-04-25 무따이 마사히꼬 일본 뇌염 바이러스 감염에 대한 불활성 백신을 위한증강된 면역원 및 그 제조방법
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2001076624A1 (en) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese b encephalitis vaccine and process for producing the same
MXPA03008882A (es) * 2001-03-27 2003-12-08 Vertex Pharma Composiciones y metodos utiles para la infeccion por hcv.
CN1305526C (zh) * 2003-12-29 2007-03-21 薛平 乙型脑炎病毒裂解疫苗及其制备方法
AU2005305347A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
EP1724338A1 (de) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methode zur Herstellung eines Impfstoffs aus inaktiviertem ganzem Westnilvirus
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
CA2710611C (en) 2007-12-26 2016-12-20 The Kitasato Institute Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine
KR20120027381A (ko) * 2009-05-25 2012-03-21 파나세아 바이오테크 리미티드 일본뇌염 백신 및 그것의 제조 방법
JP5716297B2 (ja) * 2009-06-25 2015-05-13 Jnc株式会社 クロマトグラフィー用充填剤、その製造方法、およびそれを用いたウイルス用ワクチンの製造方法
AR078253A1 (es) * 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
CN102327608B (zh) * 2010-08-27 2013-03-27 丽珠集团疫苗工程股份有限公司 一种乙型脑炎疫苗的纯化方法
SG192821A1 (en) * 2011-02-17 2013-09-30 Boehringer Ingelheim Vetmed Commercial scale process for production of prrsv
WO2014150822A2 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
CA3010049C (en) * 2016-01-15 2021-10-12 The Chemo-Sero-Therapeutic Research Institute Vaccine containing immobilized virus particles
WO2018161858A1 (en) 2017-03-06 2018-09-13 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
EP3420076B1 (de) 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Verfahren zur herstellung und charakterisierung eines virusimpfstoffes und einer virenimpfstoffzusammensetzung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147185A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
US4637936A (en) * 1984-08-10 1987-01-20 Marlen Research Corporation Aspetic food processing apparatus and method
AT393356B (de) * 1989-12-22 1991-10-10 Immuno Ag Verfahren zur herstellung von fsme-virus-antigen
CA2047041A1 (en) † 1990-07-18 1992-01-19 John A. Lewis Process for purification of hepatitis-a virus capsids
GB9022547D0 (en) † 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
JPH06153227A (ja) † 1992-10-29 1994-05-31 Victor Co Of Japan Ltd カラー信号補正回路
CN1063970C (zh) * 1994-12-06 2001-04-04 卫生部北京生物制品研究所 用鳞翅目粘虫卵巢细胞制备流行性乙脑疫苗的方法及疫苗

Also Published As

Publication number Publication date
NZ315357A (en) 1999-08-30
AU709584B2 (en) 1999-09-02
EP0841942B1 (de) 2003-01-29
EP0841942B2 (de) 2007-12-12
CN1194584A (zh) 1998-09-30
US6149917A (en) 2000-11-21
CN1122531C (zh) 2003-10-01
DE69626022T2 (de) 2003-09-11
WO1997004803A1 (fr) 1997-02-13
JPH11510151A (ja) 1999-09-07
CA2228128C (fr) 2011-03-29
CA2228128A1 (fr) 1997-02-13
DE69626022D1 (de) 2003-03-06
AU6704196A (en) 1997-02-26
KR19990036028A (ko) 1999-05-25
DE69626022T3 (de) 2008-05-08
EP0841942A1 (de) 1998-05-20

Similar Documents

Publication Publication Date Title
ATE231729T1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
IL149788A0 (en) Production of vaccines
DE69740002D1 (de) Tierzellen und verfahren für die replikation von influenza viren
ES2150938T3 (es) Produccion mejorada de taxol y taxanos mediante cultivos celulares de especies de taxus.
FR07C0012I2 (fr) Methode de desassemblage-reassemblage in vitro de particules viroides (vlp) du papillomavirus
ATE188993T1 (de) Herstellungsmethode um multiple-sklerose-virus- assoziierte infizierte zellen zu erhalten
CA2073168A1 (en) Biomass for producing virus/virus antigen
JP2633391B2 (ja) 付着的に結合した細胞を有するマトリックスおよびウイルス／ウイルス抗原の製造方法
DE69322227D1 (de) Verfahren zur herstellung von lebenden zellkulturen, die durch einen multiple sklerose assoziierten virus infiziert sind
JP2005511087A5 (de)
CA2026570A1 (en) Method for Production and Purification of Hepatitis B Vaccine
ATE486124T1 (de) Keratinozyten-kulturverfahren und verwendung davon
KR960006940A (ko) 동물세포 배양법을 이용한 뉴캣슬병 백신의 생산방법
ES2094695A1 (es) Nueva cepa de haloferax gibbonsii, halocina h7 producida por ella y procedimiento de obtencion de ambas.
CA2250714A1 (en) Animal cells and processes for the replication of influenza viruses
Abrahams Pseudorabies virus infection and RNA metabolism in hamster kidney cells
PT82505A (fr) Cellules hybrides productrices d'un antigene caracteristique du virus de l'hepatite b obtenu a partir d'hepatocytes et de cellules etablies de singe procede pour l'obtention de ces cellules hybrides et application de celles-ci a la production de l'ant-gene susdit
TH60266A (th) วิธีการสำหรับการผลิตนิวคลีโอไทด์โดยการหมัก

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties